Medidata Extends 13-Year Partnership With Tigermed
Extended collaboration will further explore the capabilities of Medidata Platform from early-phase trials to post-marketing surveillance.
Medidata announced it has extended its 13-year partnership with Tigermed, a provider of research and development solutions for the biopharmaceutical and medical device industry. This extended partnership will further leverage the Medidata Platform across the timeline of early-phase trials to post-marketing surveillance.1
In a press release, Hao Wu, executive director and co-president, Tigermed said, "Our partnership with Medidata has allowed our customers to make informed, data-driven decisions and achieve milestones faster. We are delighted to extend this collaboration and look forward to leveraging more of Medidata's technologies, including Medidata AI, as we shape the future of clinical trials worldwide."
Since 2011, Tigermed’s portfolio of work includes the completion of 300 clinical studies across therapeutic areas including oncology, vaccines, endocrine, and cardiovascular conditions, with the adoption of Medidata Platform. Moving forward with the extended partnership, Tigermed will continue to leverage the platform by automating data capture and streamlining operations.
"Tigermed exemplifies the evolving role of CROs in driving efficiencies across the clinical trial process,” Edwin Ng, senior vice president and general manager, APAC, Medidata, said in the press release. “Through this partnership, we’re able to jointly push the boundaries of trial management, improving the study experiences and ultimately delivering better outcomes for patients and sponsors around the world."
At the end of 2024, Medidata renewed another longstanding partnership with ClinChoice, a global CRO. Under this new agreement, the 13-year partnership will now include Medidata Platform as well as Clinical Data Studio. ClinChoice will leverage these platforms to streamline study data and supply management and boost trial efficiency.2
In a press release from the time, Ng said, “ClinChoice’s dedication to innovation and patient-centered approaches makes them an invaluable partner. With this renewed partnership, we look forward to empowering ClinChoice with Medidata’s advanced solutions to further streamline their trial operations, expand their global reach, and accelerate access to life-changing therapies for patients worldwide.”
In ClinChoice’s time with Medidata, the CRO has utilized a cloud environment to facilitate secure connections among patients, sites, and sponsors. During the pandemic, ClinChoice played a critical role in deploying Medidata’s Rave RTSM, which maintained patient access and optimized inventory across diverse regions and regulatory requirements through a direct-to-patient model.
Ling Zhen, global chairman and CEO of ClinChoice said, “Since our first implementation of Medidata Rave EDC in 2011, our partnership with Medidata has supported our development, starting in the US, then China, and eventually to the wider global stage. We are delighted to extend our work together to include Medidata’s Clinical Data Studio and other advanced technologies to further boost our expansion.”
Medidata announced the launch of its Clinical Data Studio in June 2024. The solution integrates clinical data from both Medidata and non-Medidata sources. It also leverages artificial intelligence to alert study teams of potential safety signals and other data issues.3
In a press release, Nimita Limaye, PhD, research vice president, life sciences R&D strategy and technology, IDC said, “As data volume and sources grow exponentially, managing this data and garnering real-time insights is becoming increasingly complex. Not only is this impacting time-to-market, but it is also delaying the timely delivery of therapies to patients, thus impacting patients' lives. By enabling users to manage all their data, both Medidata and non-Medidata data, in one place, Medidata Clinical Data Studio has the potential to disrupt the industry by accelerating clinical trials and getting therapies to patients faster.”
References
1. Medidata and Tigermed Renew Strategic Partnership Aimed at Accelerating Clinical Trials Globally. News release. Medidata. January 23, 2025. Accessed January 24, 2025. https://www.businesswire.com/news/home/20250123536880/en/Medidata-and-Tigermed-Renew-Strategic-Partnership-Aimed-at-Accelerating-Clinical-Trials-Globally
2. ClinChoice Extends 13-Year Medidata Partnership with the Addition of Clinical Data Studio to Improve Data Management and Strengthen Clinical Trial Capabilities. News release. Medidata. December 18, 2024. Accessed January 24, 2025. https://www.businesswire.com/news/home/20241218165054/en/ClinChoice-Extends-13-Year-Medidata-Partnership-with-the-Addition-of-Clinical-Data-Studio-to-Improve-Data-Management-and-Strengthen-Clinical-Trial-Capabilities
3. Medidata Launches Clinical Data Studio, Leveraging AI to Modernize the Data Experience in Clinical Trials. News release. Medidata. June 18, 2024. Accessed January 24, 2025. https://www.medidata.com/en/about-us/news-and-press/medidata-launches-clinical-data-studio-leveraging-ai-to-modernize-the-data-experience-in-clinical-trials/
Reaching Diverse Patient Populations With Personalized Treatment Methods
January 20th 2025Daejin Abidoye, head of solid tumors, oncology development, AbbVie, discusses a number of topics around diversity in clinical research including industry’s greatest challenges in reaching diverse patient populations, personalized treatment methods, recruitment strategies, and more.
Vivacity-MG3 Trial Confirms Nipocalimab’s Efficacy, Safety in Treating Generalized Myasthenia Gravis
January 23rd 2025Phase III Vivacity-MG3 trial shows that nipocalimab, an investigational FcRn blocker, significantly the improves symptoms of generalized myasthenia gravis with a manageable safety profile.
